N. Kaplan

发表

Phosphorylation of three proteins in the signaling pathway of bacterial chemotaxis

Kenji Oosawa, M. Simon, J. Hess, 1988, Cell.

Transmembrane signal transduction in bacterial chemotaxis involves ligand-dependent activation of phosphate group transfer.

M. Simon, Melvin I. Simon, J. Hess, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252

C. Rock, N. Kaplan, Joshua B Parsons, 2013, Antimicrobial Agents and Chemotherapy.

Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).

P. Sampson, N. Kaplan, D. Awrey, 2009, Bioorganic & medicinal chemistry letters.

2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI.

David D. Manning, P. Sampson, N. Kaplan, 2009, Bioorganic & medicinal chemistry letters.

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

N. Kaplan, D. Nicolau, M. Banevicius, 2013, Journal of chemotherapy.

Activity of Debio1452, a FabI Inhibitor with Potent Activity against Staphylococcus aureus and Coagulase-Negative Staphylococcus spp., Including Multidrug-Resistant Strains

Ronald N. Jones, N. Kaplan, P. Rhomberg, 2015, Antimicrobial Agents and Chemotherapy.

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

N. Kaplan, J. Karlowsky, D. Hoban, 2009, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of Staphylococcus aureus and Staphylococcus epidermidis

N. Kaplan, J. Karlowsky, D. Hoban, 2007, Antimicrobial Agents and Chemotherapy.

Acyl Carrier Protein Reductase Inhibitor AFN-1252

C. Rock, N. Kaplan, Joshua B Parsons, 2013 .

Structural studies of the capsular polysaccharide of Acinetobacter calcoaceticus BD4.

N. Kaplan, E. Rosenberg, K. Jann, 1985, European journal of biochemistry.

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects

N. Kaplan, T. Hunt, B. Hafkin, 2016, Journal of chemotherapy.

Capsular polysaccharides interfere with adherence of Acinetobacter calcoaceticus to hydrocarbon

N. Kaplan, E. Rosenberg, O. Pines, 1983 .

Exopolysaccharide Distribution of and Bioemulsifier Production by Acinetobacter calcoaceticus BD4 and BD413

N. Kaplan, E. Rosenberg, 1982, Applied and environmental microbiology.

Reconstitution of emulsifying activity of Acinetobacter calcoaceticus BD4 emulsan by using pure polysaccharide and protein

N. Kaplan, E. Rosenberg, Z Zosim, 1987, Applied and environmental microbiology.

Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

Vladimir Romanov, Molly B. Schmid, N. Kaplan, 2012, Antimicrobial Agents and Chemotherapy.

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.

N. Kaplan, Nachum Kaplan, Barry Hafkin, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

N. Kaplan, D. Awrey, J. Yethon, 2013, Journal of chemotherapy.

Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects.

N. Kaplan, T. Hunt, B. Hafkin, 2015, Future microbiology.

Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities

N. Kaplan, B. Hafkin, B. Murphy, 2015, Antimicrobial Agents and Chemotherapy.

Purification and characterization of the wild-type and mutant carboxy-terminal domains of the Escherichia coli Tar chemoreceptor

M. Simon, N. Kaplan, 1988, Journal of bacteriology.

Reduced Triclosan Susceptibility in Methicillin-Resistant Staphylococcus epidermidis

N. Kaplan, M. Schmid, 2004, Antimicrobial Agents and Chemotherapy.

DNA from Serratia marcescens confers a hydrophobic character in Escherichia coli.

N. Kaplan, M. Rosenberg, R. Doyle, 1995, FEMS microbiology letters.